AFT Pharmaceuticals (NZX: AFT, ASX: AFP) has partnered with the US-based pharmaceutical manufacturer Microsize on a long-term supply agreement of micronized active pharmaceutical ingredients (APIs), critical components of AFT’s Maxigesic Rapid pain relief medicine.
The Microsize agreement will assist AFT to source sufficient materials to supply Maxigesic Rapid in a number of markets including the US and EU.
Maxigesic Rapid, which is under the Combogesic brand in many markets, is a fast-dissolving tablet formulation of AFT’s Maxigesic family of pain relief medicines. Maxigesic Rapid allows faster release of the active ingredients, especially the ibuprofen component of the medicine. The rapid formulation has a patent until 2039, issued and under examination, in a number of countries, including the US where the patent has been granted.
AFT Managing Director Dr Hartley Atkinson commented: “We are very pleased to work with Microsize which has considerable expertise in the micronization technology that is crucial for the new rapid release Maxigesic/Combogesic formulation.”
Microsize CEO TJ Higley commented: “We are excited to have been chosen as the commercial partner to supply the blended/micronized drug product intermediate for AFT.
“Our approach of using continuous blending technologies along with the largest micronization mills in the pharmaceutical space, make our offering ideal for this product’s expected annual volumes and supply chain requirements.
“The collaboration between our companies since the early days of formulation development through clinical batches has been nothing short of spectacular and we look forward to continued expansion of this relationship.”
